Clinical trials: Oesophageal Cancer
Esophageal Squamous Cell Carcinoma
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer…
- Trial name
- NCT04644250
- Testing
- Toripalimab, Paclitaxel liposome/Carboplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Ren
Swallowing Disorders
Radiation-Related Dysphagia Development Prediction Using a Two-Step Ultrasonographic Model (R-2D-2)
Radiotherapy for head and neck cancers (H\&NC) heightens the risk of swallowing disorders (SD), impacting nutrition, quality of life, and overall health, leading to increased hospitalization and mortality.
- Trial name
- R-2D-2 (NCT06387004)
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Hopital Forcilles
Esophageal Carcinoma
Induction Chemotherapy for Locally Advanced Esophageal Cancer
Evaluate mFOLFOX6 (5-Fluorouracil, Leucovorin and Oxaliplatin) chemotherapy as induction treatment prior to standard neoadjuvant chemoradiation to decrease the rate of distant recurrence among patients with locally advanced…
- Trial name
- NCT03110926
- Testing
- mFOLFOX6, Chemoradiation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Rochester
GERD, Barrett's Esophagus
A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1
The overall objective of this study is to obtain data to evaluate whether high-resolution imaging of the gastrointestinal mucosain vivo can assist clinicians in detecting dysplastic (precancerous) areas.
- Trial name
- NCT01384695
- Testing
- Fluorescein, Proflavine hemisulfate
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Anandasabapathy, Sharmila, M.D.
Obese Patients, Tobacco Use
Nonendoscopic Screening for Barrett's Esophagus in Veterans Without Chronic Reflux
The veteran population is at increased risk for EAC and its precursor lesion, Barrett's esophagus (BE), due to increased prevalence of disease risk factors compared to the general population.
- Conditions
- Obese Patients, Tobacco Use, Veterans, Family History of Esophageal Cancer
- Trial name
- NCT06746623
- Testing
- Enrolled participants will complete Esocheck/Esoguard and diagnostic upper endoscopy.
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Louis Stokes VA Medical Center
Barrett's Esophagus, Esophageal Cancer
University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository
Aim 1: To develop a prospective tissue and blood biorepository from patients with a history of Barrett's Esophagus (BE) or esophageal cancer (ECA) presenting to UNC hospitals for routine care upper endoscopy for their condition.
- Conditions
- Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
- Trial name
- BEECAB (NCT02427269)
- Testing
- Specimen Collection
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
Esophageal Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced or recurrent esophageal cancer who have completed the previous Phase 2 study (CA139-540) and who should continue on therapy with…
- Trial name
- NCT00971841
- Testing
- Paclitaxel
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Adenocarcinoma
Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer
Esophageal adenocarcinoma (EAC) is one of the few cancers with a rising incidence in the United States, with an estimated 17,000 new cases diagnosed in 2012.
- Trial name
- NCT02606396
- Testing
- Cryotherapy, Esophagogastroduodenoscopy (EGD), Endoscopic ultrasound (EUS)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
Esophageal Cancer, Lung Cancer
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
Mixed cancer vaccines, CHP-HER2 protein and CHP-NY-ESO-1 protein, are to be studied to evaluate the safety and immune responses in patients who are positive either or both antigens.
- Conditions
- Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer
- Trial name
- NCT00291473
- Testing
- CHP-HER2, CHP-NY-ESO-1
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Esophageal Squamous Cell Carcinoma
A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a prospective, single-arm, open-label，multi-center, phase Ib/II study, aiming to evaluate the efficacy and safety of Fruquintinib combined With Cadonilimab (AK104) and Tegafur，Gimeracil and Oteracil Potassium in patients…
- Trial name
- NCT06487702
- Testing
- fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Rui-hua Xu, MD, PhD
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma
A Pilot for a Case-Control Study of Esophageal Squamous Cell Carcinoma in Western Kenya
Background: Esophageal cancer is the sixth leading cause of cancer deaths worldwide. Two primary cell types, squamous cell carcinoma and adenocarcinoma, account for most cases.
- Trial name
- NCT00901173
- Where
- Kenya
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Dysphagia
Assessment of (Chemo)RT-related Dysphagia in HNC Patients Based on Cough-related Acoustic Features
To develop this objective and easily implementable assessment method of coughing based on acoustic features of voluntary and reflex coughs, there is a primary need in identifying and comparing acoustic cough features in healthy…
- Trial name
- NCT05865756
- Testing
- Acoustic cough features analysis
- Where
- Belgium
- Volunteers
- 40 people
- Sponsor
- Jules Bordet Institute
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Tumor
Radiation Therapy and Cardiac Enzymes
The goal of this clinical research study is to learn if the radiation that you are receiving will result in an increase in certain proteins produced by the heart called cardiac biomarkers.
- Trial name
- NCT00777751
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
This was a phase 1, open-label, multiple dose, single-arm study. The mixed bacteria vaccine (MBV) was administered at a starting dose of 250 EU (1 µL) and escalated in each subject to a dose inducing the desired pyrogenic effect…
- Conditions
- Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer
- Trial name
- NCT00623831
- Testing
- Mixed bacterial vaccine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ludwig Institute for Cancer Research
Cancer of Head and Neck, Lung Cancer, Nonsmall Cell
A Multicenter Cancer Biospecimen Collection Study
This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor biopsy or who have had a recent pre-treatment tumor…
- Conditions
- Cancer of Head and Neck, Lung Cancer, Nonsmall Cell, Small-cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT04510129
- Testing
- OncoPrism™ assay
- Where
- United States
- Volunteers
- 1,650 people
- Sponsor
- Cofactor Genomics, Inc.
Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma
This is a Phase II, open-label, single-arm, multicenter study evaluating the safety and efficacy of combining Tislelizumab with induction chemoradiotherapy (CRT), followed by conversion surgery, in patients with locally advanced…
- Trial name
- NCT07039162
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Ming-Yu Lien
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Esophagus Cancer
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC.
- Trial name
- RICE-Chronos (NCT05615129)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Guangdong Provincial People's Hospital